Events
Upcoming Events
June 12, 2013
Empowered Antibodies Congress 2013, Barcelona
Sean McCarthy, D. Phil., chief executive officer, to deliver a presentation titled "Probody™ therapeutics expand the universe of potential ADC targets."
Past Events
May 3, 2013
Ninth Annual PEGS, Boston
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation titled "Probody™ Therapeutics Enable an Expanded Universe of ADC Targets."
April 9, 2013
AACR Annual Meeting, Washington, D.C.
Luc Desnoyers, Ph.D., director of cell biology, delivered an oral presentation titled "Development of a Proteolytically Activatable EGFR Probody™ for Cancer Therapy" during the "Back to the Future" mini-symposium.
January 28, 2013
Keystone Symposium on Antibodies as Drugs, Vancouver
Henry Lowman, Ph.D., chief scientific officer, presented a short talk titled, "Probody™ Therapeutics: A New Class of Proteolytically Activated Antibodies."
January 7, 2013
Biotech Showcase, San Francisco
Sean McCarthy, D. Phil, chief executive officer, delivered an overview of the company.
January 6, 2013
East / West CEO Conference, San Francisco
Sean McCarthy, D. Phil, chief executive officer, participated as a speaker at the "West Coast and International Perspectives" session.
November 14, 2012
BIO-Europe, Hamburg, Germany
Sean McCarthy, D. Phil, chief executive officer, presented an overview of the company.
November 9, 2012
Human Antibodies and Hybridomas, Orlando, Florida
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation titled "Preclinical efficacy and safety of Probody™ therapeutics."
June 25, 2012
Next Generation Protein Therapeutics Summit, San Diego
Henry Lowman, Ph.D., chief scientific officer, presented on “Safety and Efficacy of Probody™ Therapeutics in Preclinical Models”
June 18, 2012
2012 BIO International Convention, Boston
May 30, 2012
Euro-Biotech Partnering Summit, Paris
April 29, 2012
PEGS Biologics Partnering Forum, Boston
February 19, 2012
Molecular Med Tri-Con 2012, San Francisco
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation titled “Proteolytically Activated Antibodies have the Potential to Expand Therapeutic Index and Open Up New Target Space.”
January 9, 2012
BioTech Showcase, San Francisco
Sean McCarthy, D. Phil, chief executive officer, presented an overview of the company.
December 6, 2011
IBC Antibody Engineering / Therapeutics Conference, San Diego
Henry Lowman, Ph.D., chief scientific officer, presented.
November 7 - 9, 2011
Human Antibodies and Hybridomas Conference, Cannes, France
Henry Lowman, Ph.D., chief scientific officer, presented.
November 1, 2011
BioEurope – 2011, Dusseldorf, Germany
October 24 - 26, 2011
BioNetwork West, Laguna Niguel, California
June 22, 2011
Next Generation Protein Therapeutics Summit, San Francisco
Henry Lowman, Ph.D., vice president of research, presented.